Abstract:Melanoma of the skin is the sixth most common type of cancer in Europe and accounts for 3.4% of all diagnosed cancers. More alarming is the degree of recurrence that occurs with approximately 20% of patients lethally relapsing following treatment. Malignant melanoma is a highly aggressive skin cancer and metastases rapidly extend to the regional lymph nodes (stage 3) and to distal organs (stage 4). Targeted oncotherapy is one of the standard treatment for progressive stage 4 melanoma, and BRAF inhibitors (e.g. vemurafenib, dabrafenib) combined with MEK inhibitor (e.g. trametinib) can effectively counter BRAFV600E-mutated melanomas. Compared to conventional chemotherapy, targeted BRAFV600E inhibition achieves a significantly higher response rate. After a period of cancer control, however, most responsive patients develop resistance to the therapy and lethal progression. The many underlying factors potentially causing resistance to BRAF inhibitors have been extensively studied. Nevertheless, the remaining unsolved clinical questions necessitate alternative research approaches to address the molecular mechanisms underlying metastatic and treatment-resistant melanoma. In broader terms, proteomics can address clinical questions far beyond the reach of genomics, by measuring, i.e. the relative abundance of protein products, post-translational modifications (PTMs), protein localisation, turnover, protein interactions and protein function. More specifically, proteomic analysis of body fluids and tissues in a given medical and clinical setting can aid in the identification of cancer biomarkers and novel therapeutic targets. Achieving this goal requires the development of a robust and reproducible clinical proteomic platform that encompasses automated biobanking of patient samples, tissue sectioning and histological examination, efficient protein extraction, enzymatic digestion, mass spectrometry-based quantitative protein analysis by label-free or labelling technologies and/or enrichment of peptides with specific PTMs. By combining data from, e.g. phosphoproteomics and acetylomics, the protein expression profiles of different melanoma stages can provide a solid framework for understanding the biology and progression of the disease. When complemented by proteogenomics, customised protein sequence databases generated from patient-specific genomic and transcriptomic data aid in interpreting clinical proteomic biomarker data to provide a deeper and more comprehensive molecular characterisation of cellular functions underlying disease progression. In parallel to a streamlined, patient-centric, clinical proteomic pipeline, mass spectrometry-based imaging can aid in interrogating the spatial distribution of drugs and drug metabolites within tissues at single-cell resolution. These developments are an important advancement in studying drug action and efficacy in vivo and will aid in the development of more effective and safer strategies for the treatment of melanoma. A collaborative effort of gargantuan proportions between academia and healthcare professionals has led to the initiation, establishment and development of a cutting-edge cancer research centre with a specialisation in melanoma and lung cancer. The primary research focus of the European Cancer Moonshot Lund Center is to understand the impact that drugs have on cancer at an individualised and personalised level. Simultaneously, the centre increases awareness of the relentless battle against cancer and attracts global interest in the exceptional research performed at the centre.

Whole-Genome-Sequenzierung von Schleimhautmelanomen zeigt diverse Treiber und therapeutische Targets auf

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.

Whole-genome landscapes of major melanoma subtypes

Whole-exome Sequencing Reveals Mutational Profiles of Anorectal and Gynecological Melanoma

Comprehensive Genomic Profiling Reveals Distinct Patterns of Driver Mutations and Chromosomal Alterations in Acral and Mucosal Melanomas.

Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling

New Prognostic Biomarkers and Drug Targets for Skin Cutaneous Melanoma Via Comprehensive Bioinformatic Analysis and Validation

Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation

Abstract 7334: Germline mutations in cancer susceptibility genes in patients with mucosal melanoma

Whole‐exome Sequencing of Oral Mucosal Melanoma Reveals Mutational Profile and Therapeutic Targets

Distinct Genomic Traits Of Acral And Mucosal Melanomas Revealed By Targeted Mutational Profiling

Proteogenomic insights into the biology and treatment of pan-melanoma

Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations

Comprehensive Genomic Analysis of Primary Malignant Melanoma of the Esophagus Reveals Similar Genetic Patterns Compared with Epithelium-Associated Melanomas

879P Whole-genome Landscape of Head and Neck Melanomas in East Asia (China)

Whole Genome and RNA Sequencing Reveal the Distinct Genomic Landscape of Acral Melanoma.

Clonal architectures and driver mutations in metastatic melanomas

Integrated transcriptomic and immunological profiling reveals new diagnostic and prognostic models for cutaneous melanoma

Clinical protein science in translational medicine targeting malignant melanoma

MAP2K1‐mutated melanocytic tumors have reproducible histopathologic features and share similarities with melanocytic tumors with BRAF V600E mutations

Oncogenic Alterations Reveal Key Strategies for Precision Oncology in Melanoma Treatment